New publication from our CSO

PDE4D7 transcript levels as a novel biomarker to predict clinical outcomes of prostate cancer patients.

Our CSO publishes on the potential of measurement of phosphodiesterase-4D7 (PDE4D7) transcript levels to act as a novel biomarker to predict clinical outcomes of prostate cancer patients.  The PDE4D7 score may support the risk stratification of patients after local treatment to select the right timing for the start of secondary therapy for men at very high-risk of rapid disease recurrence.

http://www.eu-focus.europeanurology.com/article/S2405-4569(17)30147-5/fulltext

 



An ambitious, vibrant, growing, customer-centric company

get in touch